Aurora Cannabis Inc.

BUL:21P Stock Report

Market Cap: €332.5m

Aurora Cannabis Valuation

Is 21P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 21P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€15.94
Fair Value
72.8% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: 21P (€4.34) is trading below our estimate of fair value (€15.94)

Significantly Below Fair Value: 21P is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 21P?

Key metric: As 21P is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 21P. This is calculated by dividing 21P's market cap by their current earnings.
What is 21P's PE Ratio?
PE Ratio18.9x
EarningsCA$25.94m
Market CapCA$491.39m

Price to Earnings Ratio vs Peers

How does 21P's PE Ratio compare to its peers?

The above table shows the PE ratio for 21P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.7x
SFA Sopharma AD
11.5xn/aлв944.7m
A084110 Huons Global
12.2xn/a₩446.4b
BXPHARMA Beximco Pharmaceuticals
5.4xn/a৳34.4b
DHT Ha Tay Pharmaceutical JSC
101.5xn/a₫7.3t
21P Aurora Cannabis
18.9x23.3%€491.4m

Price-To-Earnings vs Peers: 21P is good value based on its Price-To-Earnings Ratio (18.9x) compared to the peer average (32.7x).

Price to Earnings Ratio vs Industry

How does 21P's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
21P 18.9xIndustry Avg. 22.1xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 21P is good value based on its Price-To-Earnings Ratio (18.9x) compared to the European Pharmaceuticals industry average (22.4x).

Price to Earnings Ratio vs Fair Ratio

What is 21P's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

21P PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 21P's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 6 Analysts
€4.84
Fair Value
10.4% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 19:27
End of Day Share Price 2025/01/08 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aurora Cannabis Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Frederico Yokota Choucair GomesATB Capital Markets
Tamy ChenBMO Capital Markets Equity Research
Heather BalskyBofA Global Research